CEO Garry Neil was paid $3,807,581 in fiscal year 2025, ↓ down 47.2% from fiscal year 2024 (SEC filing 0001534120-26-000022 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,807,581 ↓ Garry Neil total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 99.71% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
AVTX's next annual pay disclosure, estimated March 20, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Garry Neil | $590,000 | — | $0 | $2,732,298 | $474,950 | — | $10,333 | $3,807,581 |
| Chief Executive Officer, President and principal executive officer | ||||||||
| Taylor Boyd | 116,250 | 0 | 0 | 3,049,481 | 52,080 | 0 | 1,940 | 3,219,751 |
| Chief Business Officer | ||||||||
| Mittie Doyle | 512,500 | — | 0 | 1,030,429 | 229,600 | — | 8,028 | 1,780,557 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Garry Neil | $3,807,581 | $7,212,749 | $1,075,362 | ↓ −3,405,168 |
| Taylor Boyd | 3,219,751 | — | — | — |
| Mittie Doyle | 1,780,557 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Avalo Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper AVTX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Garry Neil | CEO | $3,807,581 |
| Mittie Doyle | Chief Medical Officer | $1,780,557 |
| Taylor Boyd | Chief Business Officer | $3,219,751 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Aaron Kantoff | Independent Director | $128,973 |
| Gilla Kaplan, Ph.D | Independent Director | $126,955 |
| Jonathan Goldman, M.D | Independent Director | $128,473 |
| June Almenoff, M.D., Ph.D | Former director (through FY2025) | $367,731 |
| Kevin Lind | Independent Director | $456,488 |
| Michael Heffernan | Chair of the Board | $509,578 |
| Mitchell Chan | Independent Director | $133,991 |
| Rita Jain, M.D | Independent Director | $177,579 |
| Samantha Truex | Independent Director | $127,473 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mittie Doyle | PSU | 72,500 | — | $1,316,600 |
| Garry Neil | PSU | 167,000 | — | 3,032,720 |
| Garry Neil | RSU | 129,733 | — | 2,355,951 |
| Garry Neil | RSU | 278 | — | 11,462 |
| Garry Neil | Option | 281,475 | 9.88 | — |
| Garry Neil | Option | 411,000 | 8.04 | — |
| Taylor Boyd | Option | 275,000 | 12.96 | — |
| Mittie Doyle | Option | 151,125 | 12.65 | — |
| Mittie Doyle | Option | 155,000 | 8.04 | — |
Compensation is designed to attract and retain individuals with superior talent, motivate employees to achieve short- and long-term results in the best interests of stockholders, and reflect a long-term commitment to the Company.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, an Aon Company |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-17 | 8,003,142 | 23,285 | 2,236 | 99.71% | Passed |
| 2022 | 2022-06-14 | 66,230,263 | 4,535,881 | 482,754 | 92.96% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-06-17 | 99.71%a |
| 2022 | 2022-06-14 | 92.96%b |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Majority of shares present and entitled to vote | Abstentions: Abstentions will have the same effect as a vote against this Proposal 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael HeffernanIndependent · Board Chair | $61,573 | $0 | $448,005 | — | — | $509,578 |
| Kevin LindIndependent · Audit (Chair) · Compensation | 0 | 0 | 456,488 | — | — | 456,488 |
| June Almenoff, M.D., Ph.DIndependent · Audit · Departed during FY | 47,917 | 61,810 | 258,004 | — | — | 367,731 |
| Rita Jain, M.DIndependent · Audit | 2,196 | 0 | 175,383 | — | — | 177,579 |
| Mitchell ChanIndependent · Audit · Not standing for re-election | 63,018 | 0 | 70,973 | — | — | 133,991 |
| Aaron KantoffIndependent · Compensation (Chair) · Nominating and Corporate Governance | 58,000 | 0 | 70,973 | — | — | 128,973 |
| Jonathan Goldman, M.DIndependent · Science and Technology Advisory Committee · Not standing for re-election | 57,500 | 0 | 70,973 | — | — | 128,473 |
| Samantha TruexIndependent · Compensation · Nominating and Corporate Governance (Chair) | 56,500 | 0 | 70,973 | — | — | 127,473 |
| Gilla Kaplan, Ph.DIndependent · Compensation · Nominating and Corporate Governance · Science and Technology Advisory Committee | 55,982 | 0 | 70,973 | — | — | 126,955 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 13,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $402,686 |
| Equity awards (grant-date value) | $61,810 |
| All other compensation | $0 |
| Total cost of the board | $464,496 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Avalo Therapeutics | 2025 | Garry Neil | $590,000 | $0 | $2,732,298 | $474,950 | $3,807,581 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Garry Neil | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Summary Compensation Table” · page 31. As printed: 3,807,581. Filing ↗ |
| 2 | Section 01, Taylor Boyd | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Summary Compensation Table” · page 31. As printed: 3,219,751. Filing ↗machine: r6 · c42 · span 409211–409221 |
| 3 | Section 01, Mittie Doyle | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Summary Compensation Table” · page 31. As printed: 1,780,557. Filing ↗ |
| 4 | Section 07, pay ratio | 10-K | 2026-03-23 | 0001534120-26-000011 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 08, Michael Heffernan | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 509,578. Filing ↗machine: span 260896–261156 |
| 6 | Section 08, Kevin Lind | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 456,488. Filing ↗machine: span 271361–271593 |
| 7 | Section 08, June Almenoff, M.D., Ph.D | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 367,731. Filing ↗machine: span 262572–262804 |
| 8 | Section 08, Rita Jain, M.D | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 177,579. Filing ↗machine: span 267114–267346 |
| 9 | Section 08, Mitchell Chan | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 133,991. Filing ↗machine: span 264020–264252 |
| 10 | Section 08, Aaron Kantoff | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 128,973. Filing ↗machine: span 268574–268806 |
| 11 | Section 08, Jonathan Goldman, M.D | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 128,473. Filing ↗machine: span 265477–265709 |
| 12 | Section 08, Samantha Truex | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 127,473. Filing ↗machine: span 273122–273354 |
| 13 | Section 08, Gilla Kaplan, Ph.D | DEF 14A | 2026-04-10 | 0001534120-26-000022 | Section “Director Compensation”. As printed: 126,955. Filing ↗machine: span 270028–270260 |
| 14 | Section 06, 2025 vote | Form 8-K | 2025-06-17 | 0001628280-25-031818 | Item 5.07 · say-on-pay result. As reported: 99.71% (votes for as printed: 8,003,142). Filing ↗ |
| 15 | Section 06, 2022 vote | Form 8-K | 2022-06-14 | 0001628280-22-017110 | Item 5.07 · say-on-pay result. As reported: 92.96% (votes for as printed: 66,230,263). Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 402,686 + equity 61,810 + all other 0 = 464,496, summed across the director compensation table rows.machine: formula: Σ = 464,496 |
| 18 | Avalo Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-10 | 0001534120-26-000022 | CEO total compensation as printed in Avalo Therapeutics's own proxy. As printed: 3,807,581. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.